Lupus erythematosus
☆ Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
Mae'n ymddangos fel erythema ychydig yn borffor.
Y frech glöyn byw sy'n ymddangos yn nodweddiadol ar yr wyneb.
References
Mae nodi a dosbarthu cutaneous lupus erythematosus (CLE) yn peri heriau diagnostig, gan ei wahaniaethu oddi wrth systemic lupus erythematosus gydag ymglymiad croen. Mae astudiaethau diweddar yn taflu goleuni ar ffactorau genetig, amgylcheddol ac imiwnolegol sy'n sail i CLE. Mae sefydlu cyffuriau yn benodol wedi dod i'r amlwg fel un o'r sbardunau pwysicaf ar gyfer CLE. Mae triniaeth yn cynnwys therapïau cyfoes a systemig, gan gynnwys bioleg addawol (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , gydag effeithiolrwydd amlwg mewn treialon clinigol.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Mae Cutaneous lupus erythematosus (CLE) yn ymdrin â materion croen amrywiol, a gallai rhai ohonynt gysylltu â phroblemau iechyd ehangach. Mae wedi'i gategoreiddio i wahanol fathau, megis acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . Mae CCLE yn cynnwys discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Mae Lupus erythematosus yn grŵp o glefydau hunanimiwn a all effeithio ar wahanol rannau o'r corff. Mae rhai mathau, fel systemic lupus erythematosus (SLE) , yn effeithio ar organau lluosog, tra bod eraill, fel cutaneous lupus erythematosus (CLE) , yn effeithio ar y croen yn bennaf. Rydym yn categoreiddio gwahanol fathau o CLE yn seiliedig ar gymysgedd o arwyddion clinigol, archwiliad meinwe, a phrofion gwaed, ond mae llawer o amrywiad rhwng unigolion. Mae problemau croen yn aml yn datblygu oherwydd ffactorau fel dod i gysylltiad â golau'r haul, ysmygu, neu rai meddyginiaethau.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Nid yw achos lupus erythematosus yn glir. Ymhlith efeilliaid union yr un fath, os effeithir ar un, mae siawns o 24% y bydd y llall hefyd. Credir hefyd bod hormonau rhyw benywaidd, golau'r haul, ysmygu, diffyg fitamin D, a rhai heintiau penodol yn cynyddu'r risg.
Gall triniaethau gynnwys NSAIDs, corticosteroidau, gwrthimiwnyddion, hydroxychloroquine, a methotrexate. Er bod corticosteroidau yn effeithiol, mae defnydd hirdymor yn arwain at sgîl-effeithiau.